Th17细胞在恶性肿瘤中作用的研究进展

doi:10.19739/j.cnki.issn1001-9510.2020.03.016

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (686 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract T helper cell 17 (Th17) is a specific subset of T helper lymphocytes determined by high secretion of IL-17 and other inflammatory cytokines. Compared with the typical Th1/Th2 cells, Th17 cells show stronger instability and plasticity, and play a part in different diseases, including infectious diseases, autoimmune disorders and cancer. Th17 cells increase tumor progression by activating angiogenesis and immunosuppressive activities. They can also mediate antitumor immune responses through changing their own phenotype and secreting related factors. Recent studies show that the infiltration of Th17 cells is associated with poor prognosis in breast cancer^[1]. In contrast, infiltration of Th17 cells notably enhanced survival in lung cancer patients^[2]. So Th17 cells are supposed as a double-edged sword in cancer. Further studies will be needed to advance our understanding of the role of Th17 cells in the immunopathogenesis of individual cancers. This article briefly reviews the differentiation and regulation of Th17 cells, the role and the latest progress of Th17 cells in the development of malignant tumors, in order to provide the improvement of more helpful ways for cancer immunotherapy.

Key words： Th17 cells IL-17 tumor immunity tumor microenvironment

Received: 20 November 2019

PACS:

R730.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIAN Jinbo
	ZHANG Luyan
	NING Fangling

Cite this article:

JIAN Jinbo,ZHANG Luyan,NING Fangling. Advanced progress of Th17 cell in malignant tumors[J]. 滨州医学院学报, 2020, 43(3): 222-224.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2020.03.016 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2020/V43/I3/222

[1] THIBAUDIN M, CHAIX M, BOIDOT R, et al. Human ectonucleotidase-expressing CD25(high) Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions[J]. Oncoimmunology, 2016, 5(1):e1055444.
[2] SONG L, MA S, CHEN L, et al. Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer[J]. Cancer sic, 2019, 110(7):2100-2109.
[3] GOLDSZMID R S, DZUTSEV A, TRINCHIERI G. Host immune response to infection and cancer: unexpected commonalities [J]. Cell host microbe, 2014, 15(3):295-305.
[4] HARRINGTON L E, HATTON R D, MANGAN P R, et al. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J]. Nat immunol, 2005, 6(11):1123-1132.
[5] PETERS A, LEE Y, KUCHROO V K. The many faces of Th17 cells[J]. Curr opin immunol, 2011, 23(6):702-706.
[6] CIOFANI M, MADAR A, GALAN C, et al. A validated regulatory network for Th17 cell specification [J]. Cell, 2012, 151(2):289-303.
[7] ZHAO M, TAN Y, PENG Q, et al. IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation [J]. Nat commun, 2018,9(1):583.
[8] GRANCHI C, MINUTOLO F. Activators of Sirtuin-1 and their Involvement in Cardioprotection[J]. Curr med chem, 2018, 25(34):4432-4456.
[9] FU B, TIAN Z, WEI H. TH17 cells in human recurrent pregnancy loss and pre-eclampsia [J]. Cell mol immunol, 2014, 11(6):564-570.
[10] QIAN X, CHEN H, WU X, et al. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis[J]. Cytokine, 2017, 89:34-44.
[11] ALIZADEH D, KATSANIS E, LARMONIER N. The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer[J]. Clin deve immunol, 2013, 2013:957878.
[12] GUERY L, HUGUES S. Th17 Cell Plasticity and Functions in Cancer Immunity[J]. Biomed res int, 2015, 2015:314620.
[13] WANG S, LI Z, HU G. Prognostic role of intratumoral IL-17A expression by immunohistochemistry in solid tumors: a meta-analysis[J]. Oncotarget, 2017, 8(39):66382-66391.
[14] WANG W, WANG Z, QIN Y, et al. Th17, synchronically increased with Tregs and Bregs, promoted by tumour cells via cell‐contact inprimary hepatic carcinoma[J]. Clin exp immunol, 2018, 192(2):181-192.
[15] ZHANG Q, LIU S, PARAJULI KR, et al. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition [J]. Oncogene, 2017, 36(5):687-699.
[16] LEE MH, TUNG-CHIEH CHANG J, et al. Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overallsurvival of head and neck cancer patients[J]. Oncotarget, 2018, 9(11):9825-9837.
[17] MERROUCHE Y, FABRE J, CURE H, et al. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells[J]. Oncotarget, 2016, 7(33):53350-53361.
[18] GUO N, SHEN G, ZHANG Y, et al. Interleukin-17 Promotes Migration and Invasion of Human Cancer Cells Through Upregulation of MTA1Expression [J]. Front oncol, 2019, 9:546.
[19] PENG D, KRYCZEK I, NAGARSHETH N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy [J].Nature, 2015, 527(7577):249-253.
[20] YANG L, LIU H, ZHANG L, et al. Effect of IL-17 in the development of colon cancer in mice [J]. Oncol lett, 2016, 12(6):4929-4936.
[21] YOU R, DEMAYO F J, LIU J, et al. IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer [J].Cancer immunol res, 2018, 6(6):645-657.
[22] KREBS C F, PANZER U. Plasticity and heterogeneity of Th17 in immune-mediated kidney diseases[J]. J autoimmun, 2018, 87:61-68.
[23] GHORESCHI K, LAURENCE A, YANG X P, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signaling[J]. Nature, 2010,467(7318):967-971.
[24] MAZZONI A, MAGGI L, LIOTTA F, et al. Biological and clinical significance of T helper 17 cell plasticity [J]. Immunology, 2019, 158(4):287-295.